--- Chain 12 for Question 102 ---
Status: USED_FOR_VOTING
Finish Reason (Model): stop
Extracted Answer: D
Prompt Tokens (Usage): 439
Completion Tokens (Usage): 7225
Reasoning Tokens (Counted): 6612
Non-Reasoning Tokens (Counted): 611
Total Tokens (Usage): N/A

--- Reasoning Content ---
Okay, so I've got this pretty complex question about molecular biology and genetics. Let me try to unpack it step by step.

The question is about a ligand-receptor pair expressed in neural crest cells and their developmental fate. The setup involves some genetic engineering with vectors and mice.

First, I'll try to visualize the vector they've constructed. It's a bicistronic vector, meaning it has two ORFs (open reading frames). The vector uses lox-Cre technology, which I remember is used for conditional gene expression, typically allowing for the removal of certain cassettes when Cre is present.

The ligand ORF is at the 5' end, fused to mCherry. So, the ligand is under the CBA promoter. Upstream of the receptor is the IRES regulatory element. IRES is involved in internal ribosome entry sites, which allows for the translation of a second ORF without needing a new ribosome to initiate. So, the ligand is expressed from the CBA promoter, then after an IRES, the receptor is expressed.

Wait, no, wait. The vector is ligand (CBA promoter) followed by IRES, then receptor. So, the ligand is first, then the IRES, then the receptor. But wait, the question says the ligand is at the 5' position, and the receptor is at the 3'. So the vector is ligand (CBA promoter) followed by IRES, then receptor.

But wait, the vector has stop cassettes. Between ligand ORF and mCherry, there's a stop in a loxP-stop-loxP cassette. Similarly, the receptor and eGFP have a lox2272-stop-lox2272 cassette. So, when the vector is used, unless the lox sites are recombined, the stops prevent expression of the fluorescent proteins.

Ah, right. So, the ligand is under the CBA promoter. The ligand ORF is followed by a loxP-stop-loxP cassette, which would stop translation unless Cre is present to excise the stop. Then, the mCherry is downstream. Similarly, the receptor ORF is followed by a lox2272-stop-lox2272 cassette, meaning that without the appropriate Cre activity (lox2272 acts with a different Cre, maybe?), the eGFP won't be expressed.

Wait, no, the way bicistronic vectors work is that the two ORFs are under different regulatory elements. But in this case, the ligand is under the CBA promoter, and the receptor is under the IRES. So the vector is arranged as CBA promoter --> ligand ORF --> loxP-stop-loxP cassette --> mCherry. Then, IRES --> receptor ORF --> lox2272-stop-lox2272 --> eGFP.

So, without Cre, the ligand is expressed (because its promoter is active), but the stop cassette prevents mCherry from being expressed. Similarly, the receptor is expressed via the IRES (which is after the ligand's ORF), but the stop cassette would prevent eGFP expression unless the appropriate Cre is used.

Wait, but in the setup, they're using a bicistronic vector with lox sites. So, perhaps when Cre is introduced, the lox sites are recognized and the stops are removed, allowing the fluorescent proteins to be expressed. So, in the absence of Cre, the mCherry and eGFP would not be expressed. But when Cre is present, it would excise the stops, allowing both mCherry and eGFP to be expressed.

But the question says that they used antibodies against the overexpressed proteins (probably the ligand and receptor) and tested on Western blot. So, if the vector is expressed, the ligand and receptor should be present. But after transfection, they were able to detect them, so the ORFs are being expressed.

But wait, the vector has the ligand under CBA, which is a strong promoter, so it's likely that the ligand is overexpressed, which makes sense why they made antibodies against it. The receptor is under the IRES, which is weaker, so perhaps less expressed.

Then, they breed a mouse model homozygous for the construct in a wild-type background. So, the mice have the construct in their genome. Then they cross it to SOX10-Cre hemizygous mice. SOX10 is a transcription factor important in neural crest development. Cre under SOX10's promoter would be active in neural crest cells, I think.

When the offspring are born, they visualize under a fluorescent confocal. They don't see a green signal, which is eGFP. So, eGFP isn't being expressed. The question is why.

The options:

A) ligand and receptor are paracrine. Paracrine means they act on nearby cells. But the question is about expression of the eGFP. If the ligand is secreted, it could act on neighboring cells, but I don't see how that directly affects the expression of eGFP in the current setup.

B) Receptor-eGFP stuck in Golgi. If the eGFP is not expressed, maybe the construct isn't properly expressed. But the question is about why it's not expressed. If the stop cassette isn't removed, the eGFP wouldn't be expressed. Alternatively, if the translation is faulty.

C) Enhancer missing. If the enhancer for expression is missing, then the construct wouldn't be expressed. But the ligand is under CBA promoter, which is strong. So if the enhancer is missing, perhaps the receptor wouldn't be expressed. But the question is about eGFP not showing up. Maybe the IRES isn't working, but I'm not sure. Alternatively, perhaps the lox sites are in the wrong orientation.

D) Receptor and eGFP not in frame. Oh, wait, the stop cassette is between receptor and eGFP. So, if the stop is not excised, the eGFP won't be expressed. But why wouldn't the stop be excised?

Wait, the vector has two different stop cassettes. The ligand's stop is loxP, and the receptor's stop is lox2272. The Cre used in the experiment is from SOX10-Cre. Does SOX10-Cre recognize lox2272? I think loxP and lox2272 are different. I remember that loxP is the standard site used with Cre, while lox2272 is a variant that is recognized by a different Cre, perhaps. Or maybe the same Cre can't recognize both. Wait, no, I think that the lox2272 is a mutant version that requires a different Cre, or maybe the same Cre can't efficiently cut it. Wait, actually, loxP is cleaved by Cre, but lox2272 is a mutated version that is only cleaved by Cre when it's in a specific context or maybe requires a different Cre variant.

Wait, but in this case, the mice are crossed with SOX10-Cre, which presumably is a standard Cre. So, the SOX10-Cre would cleave loxP sites but not lox2272 sites, perhaps. Because lox2272 is a different site. So, when the Cre is expressed in the mouse, it would only excise the loxP stop cassette in the ligand region, but not the lox2272 in the receptor region.

Wait, but the question says that the vector is lox-Cre. Wait, the vector is a bicistronic lox-Cre vector. Hmm, maybe the vector uses two different types of lox sites. So, the ligand is flanked by loxP, and the receptor is flanked by lox2272. Then, when Cre is introduced, only the loxP sites are cut. So, the ligand's stop is excised, and mCherry is expressed. But the receptor's stop (lox2272) isn't excised by the standard Cre, so eGFP isn't expressed.

But in the mouse model, the construct is present in the genome. When the mice are crossed with SOX10-Cre, which probably expresses Cre in neural crest cells, the Cre would excise the loxP sites but not the lox2272 sites. So, the ligand's stop is removed, allowing mCherry to be expressed. The receptor's stop remains, so eGFP isn't expressed. But why would they look for eGFP?

Wait, but in the question, the mouse is homozygous for the construct. The construct is in the genome, and the Cre (from SOX10-Cre) would be expressed in neural crest cells. So, the Cre would excise the loxP sites in the ligand region, allowing mCherry to be expressed. But the receptor's stop is in lox2272, which isn't cut by Cre, so eGFP isn't expressed.

But the question is about why they don't see green (eGFP) signal. But why would the eGFP not be expressed? Because the stop cassette isn't removed. Which is because the Cre can't cut the lox2272 sites. So the eGFP remains under the stop.

Wait, but the vector in the mouse would have both the loxP and lox2272 stops. So, when the Cre is introduced, only the loxP sites are cut, allowing mCherry to be expressed. The lox2272 sites remain, so the eGFP isn't expressed.

So, when they look for eGFP, it's not there. But the question is, why? So, the answer would be that the stop for eGFP wasn't excised.

Looking at the options:

Option D says the receptor and eGFP are not in frame. That would cause a frameshift, leading to a nonfunctional eGFP? Or maybe the stop is in the way. Wait, but if the stop isn't excised, the eGFP wouldn't be expressed. So, the problem is that the stop remains.

But why wouldn't the stop be excised? Because the cre can't recognize the lox2272 site. So, in the vector, the ligand's stop is loxP, which Cre can cut, but the receptor's stop is lox2272, which Cre can't cut.

So, the eGFP remains under a stop cassette. Therefore, no eGFP is expressed.

So, the reason is that the Cre can't excise the lox2272 site, so the stop remains between receptor and eGFP, preventing eGFP expression. Therefore, the answer is D? Or is it another option?

Wait, looking at the options:

A) ligand and receptor are paracrine. Hmm, not directly related. The question is about expression of eGFP, which is about the vector design.

B) Receptor-eGFP stuck in Golgi. That would affect localization, but the Western blot would probably show the receptor. They say total proteins have signal proportional to actin, so the blot shows proteins. So if the receptor is expressed, but eGFP isn't, that's the issue.

C) Enhancer missing. If the enhancer is missing, the promoter wouldn't work. But the ligand is under CBA, which is a strong promoter; so the ligand would be expressed regardless. Maybe the IRES isn't working, but I'm not sure.

D) Receptor and eGFP not in frame. If they're not in frame, the eGFP wouldn't be expressed. But wait, the stop is in between. So the construct would be receptor stop eGFP. So, if the stop isn't removed, the eGFP isn't expressed. But if the stop is removed, but the receptor and eGFP are out of frame, then the eGFP wouldn't be expressed. But in that case, the Western blot wouldn't detect the receptor either because the ORF would be disrupted.

Wait, the vector's Receptor ORF is followed by a stop cassette, then eGFP. So, when the stop is removed, the receptor would be in frame with eGFP? Or would the stop being removed allow the receptor and eGFP to be expressed as a single fusion protein? Or perhaps the eGFP is downstream in a separate ORF.

Wait, I'm a bit confused. So, the vector is ligand (CBA promoter) followed by IRES, then receptor, then stop cassette (lox2272), then eGFP. So, the IRES would allow the receptor to be expressed, and the eGFP would be a separate ORF but under the same transcription unit.

Wait, but that's not possible because the stop cassette is between the receptor and eGFP. So, the IRES is after the ligand, then the receptor ORF, then a stop, then eGFP.

Wait, I think the vector is set up so that the ligand is expressed from the CBA promoter, then after the IRES, the receptor is expressed. Each of these (ligand and receptor) have their own ORFs, and each is followed by a stop cassette. The mCherry is after the ligand's stop, which is only expressed if the stop is removed. Similarly, the eGFP is after the receptor's stop, which is only expressed if the stop is removed.

So, when Cre is present, it would excise the loxP cassette in the ligand region, allowing mCherry to be expressed. But the lox2272 cassette in the receptor region isn't cut by Cre, so eGFP remains under a stop, and isn't expressed.

In the mouse model, the Cre is from SOX10, which is expressed in neural crest cells. So, in those cells, the ligand's stop is cut, mCherry is expressed, but the receptor's stop isn't cut, so eGFP isn't expressed. Therefore, when they look for eGFP under the microscope, they don't see the green signal.

So, the reason is that the Cre used can't cut the lox2272 site, so the eGFP isn't expressed. Which option corresponds to this?

Looking at the options:

Option D says receptor and eGFP are not in frame. That would be a problem if the stop was removed but the reading frame was disrupted, but in this case, the stop isn't removed.

Alternatively, the issue is that the construct isn't being expressed because the stop is in place. So, why isn't the stop removed? Because the Cre can't cut the lox2272 cassette.

Wait, but the options don't mention anything about the Cre's ability to cut the lox sites. The options are about the setup of the construct.

Option C says the enhancer for ligand and receptor is missing. But the ligand is under a strong promoter, so that's probably not the issue here.

Option D suggests that the eGFP isn't in frame, but the stop is the main issue.

Wait, the question is in the context of the mouse not expressing eGFP. So, the eGFP isn't expressed because the stop isn't removed. The stop isn't removed because the Cre can't cut the lox2272 site. But none of the options directly address this. So, perhaps the correct answer is D?

Wait, no. Let me think again. The vector is set up so that the ligand and receptor are under their own ORFs. The mCherry and eGFP are downstream of their respective stops. The lox sites are different, so only the ligand's stop is removed, but the receptor's is not. So, the eGFP remains under a stop, not expressed. So the reason is that the stop cassette around the eGFP isn't excised, so the eGFP isn't expressed.

But the options don't have an option that says "the stop cassette wasn't excised because Cre can't recognize the lox2272 site". So, perhaps the correct answer is D, which says the receptor and eGFP are not in frame. But no, because the stop is in between them, so if the stop was removed, they would be in frame. Wait, no, the stop is between the receptor and eGFP. So, if the stop is removed, the receptor and eGFP would be in the same reading frame only if the stop is in a position that allows it.

Wait, perhaps the vector has the receptor followed by a stop cassette (lox2272) and then eGFP. So, the stop is in between. If the Cre doesn't cut the lox2272, the stop remains, so eGFP isn't expressed. That's the case here.

But the options don't directly address the lox site issue. So, perhaps the answer is D: the receptor and eGFP are not in frame. Because if the stop isn't removed, the eGFP isn't expressed. But is the stop the only issue? Or is it the frame?

Wait, perhaps the ORF of the receptor and eGFP is not in frame, so even if the stop is removed, the eGFP isn't expressed correctly. But in the vector, the receptor is followed directly by the stop cassette, then eGFP. So, the stop is between them, so if the stop is removed, the receptor would be in frame with eGFP. But if the ORFs are designed such that the frame is correct, then eGFP would be expressed.

Alternatively, perhaps the vector was designed with the lox sites in such a way that the receptor and eGFP are in separate reading frames, leading to no expression. But I'm not sure.

Alternatively, perhaps the stop is in the way, so eGFP isn't expressed regardless of the frame. So, the main issue is the stop isn't removed.

But the options don't directly state that. So, perhaps the correct answer is D.

Another thought: when the Cre is introduced, it recombines the lox sites. The ligand's stop is loxP, which is excised. The receptor's stop is lox2272, which isn't excised by the same Cre. So, the eGFP remains under the stop. Therefore, eGFP isn't expressed. So, the reason is that the Cre can't cut the lox2272 site. But none of the options talk about the lox sites.

Looking back at the options:

A) Ligand and receptor are paracrine. Doesn't explain eGFP.

B) Receptor-eGFP stuck in Golgi. That would relate to localization, but Western blot would show the receptor.

C) Enhancer missing. Unlikely because the ligand is under a strong promoter.

D) Receptor and eGFP not in frame. If the stop isn't removed, they aren't in frame because the stop is in between. Or, if the stop is removed, but the ORF is such that the frames don't match, then eGFP isn't expressed.

Wait, but in the vector, the receptor and eGFP would be in the same frame only if the stop is removed properly. If the stop isn't excised, eGFP isn't expressed. If the stop is excised but the ORFs are out of frame, then eGFP won't be expressed.

But in the mouse model, the Cre is only able to excise the ligand's loxP. The receptor's stop remains, so eGFP isn't expressed. So, the issue is that the eGFP isn't expressed because the stop isn't removed. But the options don't mention the stop.

Wait, perhaps the problem is that the IRES didn't allow the receptor to be expressed. But that's not one of the options.

Alternatively, perhaps the correct answer is D: the receptor and eGFP are not in frame. Because if the vector has a stop in between, and the stop is not removed, the eGFP isn't expressed. But the question is about why the eGFP isn't expressed when using the Cre.

Wait, maybe the correct answer is D. Because the eGFP is after the receptor, and if the stop isn't removed, it's not expressed.

Hmm, this is a bit confusing. Alternatively, perhaps the IRES is not functioning correctly. But I'm not sure.

Wait, the question says the vector is a bicistronic lox-Cre vector. So, the two ORFs are the ligand and the receptor. The ligand is under the CBA promoter, followed by an IRES, then the receptor. Then, for each, there's a stop cassette. The ligand's is loxP, and the receptor's is lox2272.

When Cre is expressed, it will excise the loxP sites, allowing mCherry to be expressed. But the lox2272 sites are not cut by Cre, so the eGFP remains under a stop.

So, the eGFP isn't expressed because the stop isn't removed. But the issue is that the Cre can't cut the lox2272 sites. So, why is that? Because in the vector, the lox sites are different.

Looking at the options, the only one that addresses the expression of eGFP is D. Because if the receptor and eGFP are not in frame, even if the stop is removed, the eGFP won't be expressed. But in the case where the stop isn't removed, the eGFP isn't expressed regardless of the frame.

Wait, but the problem is the stop hasn't been removed. So, the correct answer is that the stop isn't removed, meaning the eGFP isn't expressed. But the options don't directly address this.

Alternatively, perhaps the vector is set up incorrectly. For example, the stop is in the wrong place, leading the receptor and eGFP to be out of frame. So, even if the stop is removed, the eGFP isn't expressed.

But the question states that the mouse is homozygous for the construct in the wt background. Then, when they cross to SOX10-Cre, the Cre would only excise the loxP sites, not the lox2272. So, the eGFP remains under the stop.

Thus, why isn't the eGFP expressed? Because the stop isn't removed, and the Cre can't cut the lox2272.

But the options don't mention the lox sites. So, perhaps the correct answer is D, that the frame is incorrect.

Alternatively, perhaps the answer is C: the enhancer is missing. But the ligand is under a strong promoter, so that's probably not it.

Alternatively, perhaps the vector isn't set up correctly, so the IRES isn't working. But the Western blot would detect the receptor, so that's probably not the case.

Hmm. Alternatively, perhaps the problem is that the eGFP is not being expressed because the stop isn't removed. But why? Because the lox2272 isn't cut by the Cre.

Which of the options matches this? None directly, but option D says the receptor and eGFP are not in frame. If the stop isn't removed, they're in the same frame, but the stop is in between. So, eGFP isn't expressed because the stop is present.

But the options don't include the stop issue. So perhaps none of the options are correct, but I have to choose the best fit.

Alternatively, perhaps the correct answer is D: the receptor and eGFP are not in frame. Because if the ORFs are not in frame, then even if the stop is removed, the eGFP wouldn't be expressed. But in this case, the stop isn't removed, so the eGFP isn't expressed.

Wait, but in the mouse model, the Cre would have allowed the ligand's stop to be removed, leading to mCherry expression. But the receptor's stop remains, so eGFP isn't expressed. So, the problem is that the eGFP's stop isn't removed, because the Cre can't cut the lox2272 site.

So, which option aligns with that? None, but the closest would be D, if the frame is wrong, but that's not the case.

Alternatively, perhaps the vector wasn't properly designed, and the stop cassette isn't flanked correctly. For example, perhaps the lox sites are in the wrong orientation, so the Cre can't excise the stops.

But the question is about which option explains the lack of eGFP.

Wait, another approach: the eGFP is under the control of the receptor's lox2272 stop cassette. Since the Cre used can't cut lox2272, the eGFP isn't expressed. So the answer is that the eGFP isn't expressed because the stop wasn't excised, which is because the Cre can't cut lox2272. But this is not one of the options. So, perhaps the correct answer is D.

Alternatively, perhaps the vector design has the eGFP and receptor in the same frame, but the stop is present. So, when the stop is removed, the eGFP is expressed. But if the stop remains, eGFP isn't expressed.

But then the reason for no eGFP is the stop remains. But the options don't mention this.

I'm a bit stuck. Let me think about each option again.

Option A: Ligand and receptor are paracrine. So, the ligand is secreted and acts on neighboring cells via the receptor. But that doesn't explain why the eGFP isn't expressed in the same cell.

Option B: Receptor-eGFP stuck in Golgi. If the eGFP isn't expressed, it's not about the Golgi. The Western blot would detect the receptor if it's expressed, but the question is about eGFP.

Option C: Enhancer missing. The ligand is under CBA, which is a strong promoter. So, enhancer absence would affect both ligand and receptor, but in the Western, both are expressed.

Option D: Receptor and eGFP not in frame. If their ORFs are not in frame, the eGFP isn't expressed. But why? Because the stop is in between. So, if the stop is removed, they would be in frame, assuming correct design. But in the mouse, the stop isn't removed, so the eGFP isn't expressed.

Wait, but in the vector, the eGFP is after the receptor. The vector is designed so that when the lox2272 stop is removed, the receptor and eGFP are in frame, allowing eGFP to be expressed as a fusion or as separate proteins. But since the Cre can't remove the lox2272, the stop remains, preventing eGFP expression.

But the question is why the eGFP isn't expressed. The direct reason is that the stop isn't removed, but the underlying reason is that the Cre can't cut the lox2272. But none of the options talk about the lox sites.

Wait, perhaps option D is correct because if the stop is present, the eGFP is not expressed regardless of the frame. But that seems more about the presence of the stop, not the frame.

Alternatively, perhaps the construct was designed with the eGFP in a different reading frame, so even if the stop is removed, eGFP isn't expressed correctly. But without knowing, it's hard to say.

Alternatively, perhaps the issue is that the IRES doesn't support the expression of the receptor correctly. But the Western blot uses antibodies against the receptor, so if the receptor is expressed, the blot would show it. So, the eGFP issue is separate.

Hmm, perhaps the correct answer is D. Because if the eGFP isn't in frame, it won't be expressed. But I'm not fully confident. Another approach: the vector uses two different lox sites, so only one of the stops is excised. The ligand's stop is loxP, so with Cre, it's excised. The receptor's stop is lox2272, which isn't excised. So, eGFP isn't expressed.

So, the reason is that the Cre doesn't cut lox2272. But the options don't have that. So, perhaps the correct answer is D.

Alternatively, perhaps I'm overcomplicating this. The vector uses IRES, which is used to express the receptor. But if the IRES isn't working, the receptor isn't expressed, so no eGFP. But the ligand is expressed, so you'd see mCherry. But the question is about eGFP.

Wait, but the problem is that the eGFP isn't expressed. So, why?

Another angle: the eGFP is under the same transcriptional unit as the receptor, but after a stop. So, without the stop being removed, the eGFP isn't expressed. So, the stop remains, and eGFP isn't expressed. But the stop isn't removed because the Cre can't cut the lox2272.

But the question is why the eGFP isn't expressed. The answer must be in the options.

Wait, perhaps the correct answer is D: the receptor and eGFP are not in frame. Because the vector was designed as ligand-IRES-receptor-lox2272-stop-eGFP. So, if the stop is not removed, the eGFP isn't expressed. But if the stop is removed, are the receptor and eGFP in frame? If the vector was designed correctly, yes. If not, no. But the issue here is that the stop isn't removed, so the eGFP isn't expressed.

But that's not directly any of the options.

Alternatively, perhaps the correct answer is D: the receptor and eGFP are not in frame. So, even if the stop is removed, the eGFP isn't expressed. But in the mouse model, the stop isn't removed, so the eGFP isn't expressed regardless.

Hmm, this is quite challenging. Another approach: the vector is designed so that when Cre is expressed, the stops are removed, allowing eGFP and mCherry to be expressed. But in this case, the eGFP isn't expressed. So, the problem is that the eGFP's stop isn't removed. Because the vector uses different lox sites, and the Cre can't cut them.

But since the options don't mention this, perhaps the correct answer is D: the receptor and eGFP are not in frame.

After considering all this, I think the correct answer is D.


--- Final Answer Content ---


The question involves a bicistronic lox-Cre vector designed to express a ligand and a receptor, with fluorescent markers (mCherry and eGFP) downstream of stop cassettes. The ligand is under the CBA promoter, and the receptor is under an IRES element. The ligand's stop cassette is flanked by loxP sites, while the receptor's stop cassette is flanked by lox2272 sites. The vector is introduced into a mouse model, and SOX10-Cre mice are used to excise the stop cassettes in neural crest cells. Despite this, no green signal (eGFP) is observed under the confocal microscope.

### Key Analysis of the Options:

1. **Option A: Ligand and receptor are in a paracrine relationship**  
   This option suggests that the ligand acts on neighboring cells via the receptor. However, the question focuses on why eGFP is not expressed in the same cell, not on intercellular signaling. This option does not explain the lack of eGFP expression.

2. **Option B: The receptor-eGFP construct is stuck in the Golgi**  
   If the receptor-eGFP construct were stuck in the Golgi, it would affect localization but not necessarily expression. The Western blot would still detect the receptor if it is synthesized, but the question specifically highlights the absence of eGFP. This option does not address the core issue.

3. **Option C: The enhancer for the ligand and receptor expression is missing**  
   The ligand is under the CBA promoter, which is a strong promoter, so its expression is unlikely to be affected by the absence of an enhancer. While the receptor's expression might be weaker due to the IRES element, the Western blot would still detect the receptor if it is expressed. This option does not directly explain the lack of eGFP expression.

4. **Option D: The receptor and eGFP are not in frame**  
   The vector design places the receptor followed by a stop cassette (lox2272) and then eGFP. If the stop cassette is not excised, eGFP will not be expressed. The SOX10-Cre used in the experiment excises loxP sites but not lox2272 sites, leaving the stop cassette intact and preventing eGFP expression. This aligns with the observation of no green signal, as the eGFP remains under the stop cassette and is not expressed.

### Conclusion:
The absence of eGFP expression is due to the stop cassette flanking the receptor and eGFP, which is not excised by the SOX10-Cre used in the experiment. This prevents eGFP from being expressed. Among the options provided, the most plausible explanation is that the receptor and eGFP are not in frame, as the stop cassette disrupts their expression. 

Answer: D

--- Full Content ---
Okay, so I've got this pretty complex question about molecular biology and genetics. Let me try to unpack it step by step.

The question is about a ligand-receptor pair expressed in neural crest cells and their developmental fate. The setup involves some genetic engineering with vectors and mice.

First, I'll try to visualize the vector they've constructed. It's a bicistronic vector, meaning it has two ORFs (open reading frames). The vector uses lox-Cre technology, which I remember is used for conditional gene expression, typically allowing for the removal of certain cassettes when Cre is present.

The ligand ORF is at the 5' end, fused to mCherry. So, the ligand is under the CBA promoter. Upstream of the receptor is the IRES regulatory element. IRES is involved in internal ribosome entry sites, which allows for the translation of a second ORF without needing a new ribosome to initiate. So, the ligand is expressed from the CBA promoter, then after an IRES, the receptor is expressed.

Wait, no, wait. The vector is ligand (CBA promoter) followed by IRES, then receptor. So, the ligand is first, then the IRES, then the receptor. But wait, the question says the ligand is at the 5' position, and the receptor is at the 3'. So the vector is ligand (CBA promoter) followed by IRES, then receptor.

But wait, the vector has stop cassettes. Between ligand ORF and mCherry, there's a stop in a loxP-stop-loxP cassette. Similarly, the receptor and eGFP have a lox2272-stop-lox2272 cassette. So, when the vector is used, unless the lox sites are recombined, the stops prevent expression of the fluorescent proteins.

Ah, right. So, the ligand is under the CBA promoter. The ligand ORF is followed by a loxP-stop-loxP cassette, which would stop translation unless Cre is present to excise the stop. Then, the mCherry is downstream. Similarly, the receptor ORF is followed by a lox2272-stop-lox2272 cassette, meaning that without the appropriate Cre activity (lox2272 acts with a different Cre, maybe?), the eGFP won't be expressed.

Wait, no, the way bicistronic vectors work is that the two ORFs are under different regulatory elements. But in this case, the ligand is under the CBA promoter, and the receptor is under the IRES. So the vector is arranged as CBA promoter --> ligand ORF --> loxP-stop-loxP cassette --> mCherry. Then, IRES --> receptor ORF --> lox2272-stop-lox2272 --> eGFP.

So, without Cre, the ligand is expressed (because its promoter is active), but the stop cassette prevents mCherry from being expressed. Similarly, the receptor is expressed via the IRES (which is after the ligand's ORF), but the stop cassette would prevent eGFP expression unless the appropriate Cre is used.

Wait, but in the setup, they're using a bicistronic vector with lox sites. So, perhaps when Cre is introduced, the lox sites are recognized and the stops are removed, allowing the fluorescent proteins to be expressed. So, in the absence of Cre, the mCherry and eGFP would not be expressed. But when Cre is present, it would excise the stops, allowing both mCherry and eGFP to be expressed.

But the question says that they used antibodies against the overexpressed proteins (probably the ligand and receptor) and tested on Western blot. So, if the vector is expressed, the ligand and receptor should be present. But after transfection, they were able to detect them, so the ORFs are being expressed.

But wait, the vector has the ligand under CBA, which is a strong promoter, so it's likely that the ligand is overexpressed, which makes sense why they made antibodies against it. The receptor is under the IRES, which is weaker, so perhaps less expressed.

Then, they breed a mouse model homozygous for the construct in a wild-type background. So, the mice have the construct in their genome. Then they cross it to SOX10-Cre hemizygous mice. SOX10 is a transcription factor important in neural crest development. Cre under SOX10's promoter would be active in neural crest cells, I think.

When the offspring are born, they visualize under a fluorescent confocal. They don't see a green signal, which is eGFP. So, eGFP isn't being expressed. The question is why.

The options:

A) ligand and receptor are paracrine. Paracrine means they act on nearby cells. But the question is about expression of the eGFP. If the ligand is secreted, it could act on neighboring cells, but I don't see how that directly affects the expression of eGFP in the current setup.

B) Receptor-eGFP stuck in Golgi. If the eGFP is not expressed, maybe the construct isn't properly expressed. But the question is about why it's not expressed. If the stop cassette isn't removed, the eGFP wouldn't be expressed. Alternatively, if the translation is faulty.

C) Enhancer missing. If the enhancer for expression is missing, then the construct wouldn't be expressed. But the ligand is under CBA promoter, which is strong. So if the enhancer is missing, perhaps the receptor wouldn't be expressed. But the question is about eGFP not showing up. Maybe the IRES isn't working, but I'm not sure. Alternatively, perhaps the lox sites are in the wrong orientation.

D) Receptor and eGFP not in frame. Oh, wait, the stop cassette is between receptor and eGFP. So, if the stop is not excised, the eGFP won't be expressed. But why wouldn't the stop be excised?

Wait, the vector has two different stop cassettes. The ligand's stop is loxP, and the receptor's stop is lox2272. The Cre used in the experiment is from SOX10-Cre. Does SOX10-Cre recognize lox2272? I think loxP and lox2272 are different. I remember that loxP is the standard site used with Cre, while lox2272 is a variant that is recognized by a different Cre, perhaps. Or maybe the same Cre can't recognize both. Wait, no, I think that the lox2272 is a mutant version that requires a different Cre, or maybe the same Cre can't efficiently cut it. Wait, actually, loxP is cleaved by Cre, but lox2272 is a mutated version that is only cleaved by Cre when it's in a specific context or maybe requires a different Cre variant.

Wait, but in this case, the mice are crossed with SOX10-Cre, which presumably is a standard Cre. So, the SOX10-Cre would cleave loxP sites but not lox2272 sites, perhaps. Because lox2272 is a different site. So, when the Cre is expressed in the mouse, it would only excise the loxP stop cassette in the ligand region, but not the lox2272 in the receptor region.

Wait, but the question says that the vector is lox-Cre. Wait, the vector is a bicistronic lox-Cre vector. Hmm, maybe the vector uses two different types of lox sites. So, the ligand is flanked by loxP, and the receptor is flanked by lox2272. Then, when Cre is introduced, only the loxP sites are cut. So, the ligand's stop is excised, and mCherry is expressed. But the receptor's stop (lox2272) isn't excised by the standard Cre, so eGFP isn't expressed.

But in the mouse model, the construct is present in the genome. When the mice are crossed with SOX10-Cre, which probably expresses Cre in neural crest cells, the Cre would excise the loxP sites but not the lox2272 sites. So, the ligand's stop is removed, allowing mCherry to be expressed. The receptor's stop remains, so eGFP isn't expressed. But why would they look for eGFP?

Wait, but in the question, the mouse is homozygous for the construct. The construct is in the genome, and the Cre (from SOX10-Cre) would be expressed in neural crest cells. So, the Cre would excise the loxP sites in the ligand region, allowing mCherry to be expressed. But the receptor's stop is in lox2272, which isn't cut by Cre, so eGFP isn't expressed.

But the question is about why they don't see green (eGFP) signal. But why would the eGFP not be expressed? Because the stop cassette isn't removed. Which is because the Cre can't cut the lox2272 sites. So the eGFP remains under the stop.

Wait, but the vector in the mouse would have both the loxP and lox2272 stops. So, when the Cre is introduced, only the loxP sites are cut, allowing mCherry to be expressed. The lox2272 sites remain, so the eGFP isn't expressed.

So, when they look for eGFP, it's not there. But the question is, why? So, the answer would be that the stop for eGFP wasn't excised.

Looking at the options:

Option D says the receptor and eGFP are not in frame. That would cause a frameshift, leading to a nonfunctional eGFP? Or maybe the stop is in the way. Wait, but if the stop isn't excised, the eGFP wouldn't be expressed. So, the problem is that the stop remains.

But why wouldn't the stop be excised? Because the cre can't recognize the lox2272 site. So, in the vector, the ligand's stop is loxP, which Cre can cut, but the receptor's stop is lox2272, which Cre can't cut.

So, the eGFP remains under a stop cassette. Therefore, no eGFP is expressed.

So, the reason is that the Cre can't excise the lox2272 site, so the stop remains between receptor and eGFP, preventing eGFP expression. Therefore, the answer is D? Or is it another option?

Wait, looking at the options:

A) ligand and receptor are paracrine. Hmm, not directly related. The question is about expression of eGFP, which is about the vector design.

B) Receptor-eGFP stuck in Golgi. That would affect localization, but the Western blot would probably show the receptor. They say total proteins have signal proportional to actin, so the blot shows proteins. So if the receptor is expressed, but eGFP isn't, that's the issue.

C) Enhancer missing. If the enhancer is missing, the promoter wouldn't work. But the ligand is under CBA, which is a strong promoter; so the ligand would be expressed regardless. Maybe the IRES isn't working, but I'm not sure.

D) Receptor and eGFP not in frame. If they're not in frame, the eGFP wouldn't be expressed. But wait, the stop is in between. So the construct would be receptor stop eGFP. So, if the stop isn't removed, the eGFP isn't expressed. But if the stop is removed, but the receptor and eGFP are out of frame, then the eGFP wouldn't be expressed. But in that case, the Western blot wouldn't detect the receptor either because the ORF would be disrupted.

Wait, the vector's Receptor ORF is followed by a stop cassette, then eGFP. So, when the stop is removed, the receptor would be in frame with eGFP? Or would the stop being removed allow the receptor and eGFP to be expressed as a single fusion protein? Or perhaps the eGFP is downstream in a separate ORF.

Wait, I'm a bit confused. So, the vector is ligand (CBA promoter) followed by IRES, then receptor, then stop cassette (lox2272), then eGFP. So, the IRES would allow the receptor to be expressed, and the eGFP would be a separate ORF but under the same transcription unit.

Wait, but that's not possible because the stop cassette is between the receptor and eGFP. So, the IRES is after the ligand, then the receptor ORF, then a stop, then eGFP.

Wait, I think the vector is set up so that the ligand is expressed from the CBA promoter, then after the IRES, the receptor is expressed. Each of these (ligand and receptor) have their own ORFs, and each is followed by a stop cassette. The mCherry is after the ligand's stop, which is only expressed if the stop is removed. Similarly, the eGFP is after the receptor's stop, which is only expressed if the stop is removed.

So, when Cre is present, it would excise the loxP cassette in the ligand region, allowing mCherry to be expressed. But the lox2272 cassette in the receptor region isn't cut by Cre, so eGFP remains under a stop, and isn't expressed.

In the mouse model, the Cre is from SOX10, which is expressed in neural crest cells. So, in those cells, the ligand's stop is cut, mCherry is expressed, but the receptor's stop isn't cut, so eGFP isn't expressed. Therefore, when they look for eGFP under the microscope, they don't see the green signal.

So, the reason is that the Cre used can't cut the lox2272 site, so the eGFP isn't expressed. Which option corresponds to this?

Looking at the options:

Option D says receptor and eGFP are not in frame. That would be a problem if the stop was removed but the reading frame was disrupted, but in this case, the stop isn't removed.

Alternatively, the issue is that the construct isn't being expressed because the stop is in place. So, why isn't the stop removed? Because the Cre can't cut the lox2272 cassette.

Wait, but the options don't mention anything about the Cre's ability to cut the lox sites. The options are about the setup of the construct.

Option C says the enhancer for ligand and receptor is missing. But the ligand is under a strong promoter, so that's probably not the issue here.

Option D suggests that the eGFP isn't in frame, but the stop is the main issue.

Wait, the question is in the context of the mouse not expressing eGFP. So, the eGFP isn't expressed because the stop isn't removed. The stop isn't removed because the Cre can't cut the lox2272 site. But none of the options directly address this. So, perhaps the correct answer is D?

Wait, no. Let me think again. The vector is set up so that the ligand and receptor are under their own ORFs. The mCherry and eGFP are downstream of their respective stops. The lox sites are different, so only the ligand's stop is removed, but the receptor's is not. So, the eGFP remains under a stop, not expressed. So the reason is that the stop cassette around the eGFP isn't excised, so the eGFP isn't expressed.

But the options don't have an option that says "the stop cassette wasn't excised because Cre can't recognize the lox2272 site". So, perhaps the correct answer is D, which says the receptor and eGFP are not in frame. But no, because the stop is in between them, so if the stop was removed, they would be in frame. Wait, no, the stop is between the receptor and eGFP. So, if the stop is removed, the receptor and eGFP would be in the same reading frame only if the stop is in a position that allows it.

Wait, perhaps the vector has the receptor followed by a stop cassette (lox2272) and then eGFP. So, the stop is in between. If the Cre doesn't cut the lox2272, the stop remains, so eGFP isn't expressed. That's the case here.

But the options don't directly address the lox site issue. So, perhaps the answer is D: the receptor and eGFP are not in frame. Because if the stop isn't removed, the eGFP isn't expressed. But is the stop the only issue? Or is it the frame?

Wait, perhaps the ORF of the receptor and eGFP is not in frame, so even if the stop is removed, the eGFP isn't expressed correctly. But in the vector, the receptor is followed directly by the stop cassette, then eGFP. So, the stop is between them, so if the stop is removed, the receptor would be in frame with eGFP. But if the ORFs are designed such that the frame is correct, then eGFP would be expressed.

Alternatively, perhaps the vector was designed with the lox sites in such a way that the receptor and eGFP are in separate reading frames, leading to no expression. But I'm not sure.

Alternatively, perhaps the stop is in the way, so eGFP isn't expressed regardless of the frame. So, the main issue is the stop isn't removed.

But the options don't directly state that. So, perhaps the correct answer is D.

Another thought: when the Cre is introduced, it recombines the lox sites. The ligand's stop is loxP, which is excised. The receptor's stop is lox2272, which isn't excised by the same Cre. So, the eGFP remains under the stop. Therefore, eGFP isn't expressed. So, the reason is that the Cre can't cut the lox2272 site. But none of the options talk about the lox sites.

Looking back at the options:

A) Ligand and receptor are paracrine. Doesn't explain eGFP.

B) Receptor-eGFP stuck in Golgi. That would relate to localization, but Western blot would show the receptor.

C) Enhancer missing. Unlikely because the ligand is under a strong promoter.

D) Receptor and eGFP not in frame. If the stop isn't removed, they aren't in frame because the stop is in between. Or, if the stop is removed, but the ORF is such that the frames don't match, then eGFP isn't expressed.

Wait, but in the vector, the receptor and eGFP would be in the same frame only if the stop is removed properly. If the stop isn't excised, eGFP isn't expressed. If the stop is excised but the ORFs are out of frame, then eGFP won't be expressed.

But in the mouse model, the Cre is only able to excise the ligand's loxP. The receptor's stop remains, so eGFP isn't expressed. So, the issue is that the eGFP isn't expressed because the stop isn't removed. But the options don't mention the stop.

Wait, perhaps the problem is that the IRES didn't allow the receptor to be expressed. But that's not one of the options.

Alternatively, perhaps the correct answer is D: the receptor and eGFP are not in frame. Because if the vector has a stop in between, and the stop is not removed, the eGFP isn't expressed. But the question is about why the eGFP isn't expressed when using the Cre.

Wait, maybe the correct answer is D. Because the eGFP is after the receptor, and if the stop isn't removed, it's not expressed.

Hmm, this is a bit confusing. Alternatively, perhaps the IRES is not functioning correctly. But I'm not sure.

Wait, the question says the vector is a bicistronic lox-Cre vector. So, the two ORFs are the ligand and the receptor. The ligand is under the CBA promoter, followed by an IRES, then the receptor. Then, for each, there's a stop cassette. The ligand's is loxP, and the receptor's is lox2272.

When Cre is expressed, it will excise the loxP sites, allowing mCherry to be expressed. But the lox2272 sites are not cut by Cre, so the eGFP remains under a stop.

So, the eGFP isn't expressed because the stop isn't removed. But the issue is that the Cre can't cut the lox2272 sites. So, why is that? Because in the vector, the lox sites are different.

Looking at the options, the only one that addresses the expression of eGFP is D. Because if the receptor and eGFP are not in frame, even if the stop is removed, the eGFP won't be expressed. But in the case where the stop isn't removed, the eGFP isn't expressed regardless of the frame.

Wait, but the problem is the stop hasn't been removed. So, the correct answer is that the stop isn't removed, meaning the eGFP isn't expressed. But the options don't directly address this.

Alternatively, perhaps the vector is set up incorrectly. For example, the stop is in the wrong place, leading the receptor and eGFP to be out of frame. So, even if the stop is removed, the eGFP isn't expressed.

But the question states that the mouse is homozygous for the construct in the wt background. Then, when they cross to SOX10-Cre, the Cre would only excise the loxP sites, not the lox2272. So, the eGFP remains under the stop.

Thus, why isn't the eGFP expressed? Because the stop isn't removed, and the Cre can't cut the lox2272.

But the options don't mention the lox sites. So, perhaps the correct answer is D, that the frame is incorrect.

Alternatively, perhaps the answer is C: the enhancer is missing. But the ligand is under a strong promoter, so that's probably not it.

Alternatively, perhaps the vector isn't set up correctly, so the IRES isn't working. But the Western blot would detect the receptor, so that's probably not the case.

Hmm. Alternatively, perhaps the problem is that the eGFP is not being expressed because the stop isn't removed. But why? Because the lox2272 isn't cut by the Cre.

Which of the options matches this? None directly, but option D says the receptor and eGFP are not in frame. If the stop isn't removed, they're in the same frame, but the stop is in between. So, eGFP isn't expressed because the stop is present.

But the options don't include the stop issue. So perhaps none of the options are correct, but I have to choose the best fit.

Alternatively, perhaps the correct answer is D: the receptor and eGFP are not in frame. Because if the ORFs are not in frame, then even if the stop is removed, the eGFP wouldn't be expressed. But in this case, the stop isn't removed, so the eGFP isn't expressed.

Wait, but in the mouse model, the Cre would have allowed the ligand's stop to be removed, leading to mCherry expression. But the receptor's stop remains, so eGFP isn't expressed. So, the problem is that the eGFP's stop isn't removed, because the Cre can't cut the lox2272 site.

So, which option aligns with that? None, but the closest would be D, if the frame is wrong, but that's not the case.

Alternatively, perhaps the vector wasn't properly designed, and the stop cassette isn't flanked correctly. For example, perhaps the lox sites are in the wrong orientation, so the Cre can't excise the stops.

But the question is about which option explains the lack of eGFP.

Wait, another approach: the eGFP is under the control of the receptor's lox2272 stop cassette. Since the Cre used can't cut lox2272, the eGFP isn't expressed. So the answer is that the eGFP isn't expressed because the stop wasn't excised, which is because the Cre can't cut lox2272. But this is not one of the options. So, perhaps the correct answer is D.

Alternatively, perhaps the vector design has the eGFP and receptor in the same frame, but the stop is present. So, when the stop is removed, the eGFP is expressed. But if the stop remains, eGFP isn't expressed.

But then the reason for no eGFP is the stop remains. But the options don't mention this.

I'm a bit stuck. Let me think about each option again.

Option A: Ligand and receptor are paracrine. So, the ligand is secreted and acts on neighboring cells via the receptor. But that doesn't explain why the eGFP isn't expressed in the same cell.

Option B: Receptor-eGFP stuck in Golgi. If the eGFP isn't expressed, it's not about the Golgi. The Western blot would detect the receptor if it's expressed, but the question is about eGFP.

Option C: Enhancer missing. The ligand is under CBA, which is a strong promoter. So, enhancer absence would affect both ligand and receptor, but in the Western, both are expressed.

Option D: Receptor and eGFP not in frame. If their ORFs are not in frame, the eGFP isn't expressed. But why? Because the stop is in between. So, if the stop is removed, they would be in frame, assuming correct design. But in the mouse, the stop isn't removed, so the eGFP isn't expressed.

Wait, but in the vector, the eGFP is after the receptor. The vector is designed so that when the lox2272 stop is removed, the receptor and eGFP are in frame, allowing eGFP to be expressed as a fusion or as separate proteins. But since the Cre can't remove the lox2272, the stop remains, preventing eGFP expression.

But the question is why the eGFP isn't expressed. The direct reason is that the stop isn't removed, but the underlying reason is that the Cre can't cut the lox2272. But none of the options talk about the lox sites.

Wait, perhaps option D is correct because if the stop is present, the eGFP is not expressed regardless of the frame. But that seems more about the presence of the stop, not the frame.

Alternatively, perhaps the construct was designed with the eGFP in a different reading frame, so even if the stop is removed, eGFP isn't expressed correctly. But without knowing, it's hard to say.

Alternatively, perhaps the issue is that the IRES doesn't support the expression of the receptor correctly. But the Western blot uses antibodies against the receptor, so if the receptor is expressed, the blot would show it. So, the eGFP issue is separate.

Hmm, perhaps the correct answer is D. Because if the eGFP isn't in frame, it won't be expressed. But I'm not fully confident. Another approach: the vector uses two different lox sites, so only one of the stops is excised. The ligand's stop is loxP, so with Cre, it's excised. The receptor's stop is lox2272, which isn't excised. So, eGFP isn't expressed.

So, the reason is that the Cre doesn't cut lox2272. But the options don't have that. So, perhaps the correct answer is D.

Alternatively, perhaps I'm overcomplicating this. The vector uses IRES, which is used to express the receptor. But if the IRES isn't working, the receptor isn't expressed, so no eGFP. But the ligand is expressed, so you'd see mCherry. But the question is about eGFP.

Wait, but the problem is that the eGFP isn't expressed. So, why?

Another angle: the eGFP is under the same transcriptional unit as the receptor, but after a stop. So, without the stop being removed, the eGFP isn't expressed. So, the stop remains, and eGFP isn't expressed. But the stop isn't removed because the Cre can't cut the lox2272.

But the question is why the eGFP isn't expressed. The answer must be in the options.

Wait, perhaps the correct answer is D: the receptor and eGFP are not in frame. Because the vector was designed as ligand-IRES-receptor-lox2272-stop-eGFP. So, if the stop is not removed, the eGFP isn't expressed. But if the stop is removed, are the receptor and eGFP in frame? If the vector was designed correctly, yes. If not, no. But the issue here is that the stop isn't removed, so the eGFP isn't expressed.

But that's not directly any of the options.

Alternatively, perhaps the correct answer is D: the receptor and eGFP are not in frame. So, even if the stop is removed, the eGFP isn't expressed. But in the mouse model, the stop isn't removed, so the eGFP isn't expressed regardless.

Hmm, this is quite challenging. Another approach: the vector is designed so that when Cre is expressed, the stops are removed, allowing eGFP and mCherry to be expressed. But in this case, the eGFP isn't expressed. So, the problem is that the eGFP's stop isn't removed. Because the vector uses different lox sites, and the Cre can't cut them.

But since the options don't mention this, perhaps the correct answer is D: the receptor and eGFP are not in frame.

After considering all this, I think the correct answer is D.


The question involves a bicistronic lox-Cre vector designed to express a ligand and a receptor, with fluorescent markers (mCherry and eGFP) downstream of stop cassettes. The ligand is under the CBA promoter, and the receptor is under an IRES element. The ligand's stop cassette is flanked by loxP sites, while the receptor's stop cassette is flanked by lox2272 sites. The vector is introduced into a mouse model, and SOX10-Cre mice are used to excise the stop cassettes in neural crest cells. Despite this, no green signal (eGFP) is observed under the confocal microscope.

### Key Analysis of the Options:

1. **Option A: Ligand and receptor are in a paracrine relationship**  
   This option suggests that the ligand acts on neighboring cells via the receptor. However, the question focuses on why eGFP is not expressed in the same cell, not on intercellular signaling. This option does not explain the lack of eGFP expression.

2. **Option B: The receptor-eGFP construct is stuck in the Golgi**  
   If the receptor-eGFP construct were stuck in the Golgi, it would affect localization but not necessarily expression. The Western blot would still detect the receptor if it is synthesized, but the question specifically highlights the absence of eGFP. This option does not address the core issue.

3. **Option C: The enhancer for the ligand and receptor expression is missing**  
   The ligand is under the CBA promoter, which is a strong promoter, so its expression is unlikely to be affected by the absence of an enhancer. While the receptor's expression might be weaker due to the IRES element, the Western blot would still detect the receptor if it is expressed. This option does not directly explain the lack of eGFP expression.

4. **Option D: The receptor and eGFP are not in frame**  
   The vector design places the receptor followed by a stop cassette (lox2272) and then eGFP. If the stop cassette is not excised, eGFP will not be expressed. The SOX10-Cre used in the experiment excises loxP sites but not lox2272 sites, leaving the stop cassette intact and preventing eGFP expression. This aligns with the observation of no green signal, as the eGFP remains under the stop cassette and is not expressed.

### Conclusion:
The absence of eGFP expression is due to the stop cassette flanking the receptor and eGFP, which is not excised by the SOX10-Cre used in the experiment. This prevents eGFP from being expressed. Among the options provided, the most plausible explanation is that the receptor and eGFP are not in frame, as the stop cassette disrupts their expression. 

Answer: D